 PARIS, France NEW ORLEANS, La.-- BUSINESS WIRE --METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed refractory AML at the American Society of Hematologys ASH 64th Annual Meeting. Metafora worked with the Wugen team to characterize Wugens drug candidate WU-NK-01, a novel, off-the-shelf therapy for AML, which Wugen expects to advance to the clinic. 